Why Is This Nano-Cap Glucotrack Stock Trading Higher On Wednesday?
GCTK stock rose 59.9% after strong clinical study results. The study showed excellent accuracy for the Continuous Blood Glucose Monitor. 92% of measurements were accurate, validating the device's safety and performance. A long-term feasibility study is planned for Q3 2025. GCTK offers a less invasive alternative to traditional glucose monitors.
View signal analysis